ClinicalTrials.gg
CompletedNCT03216473Updated Jul 13, 2017

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm

A Phase 3 interventional study of Neuronox and Botox in Essential Blepharospasm, sponsored by Medy-Tox. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-13.

Sponsored by Medy-Tox · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled May 2016, registered Jul 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This clinical study evaluates the efficacy and safety of Neuronox compared with Botox in adults with essential blepharospasm.

Read the detailed description

Subjects are randomly assigned into the two groups at the ratio of 1:1. The purpose of study is to confirm the non-inferiority of Neuronox to Botox in terms of the efficacy and safety in subjects with essential blepharospasm.

02

Conditions studied

  • Essential Blepharospasm
03

In context

Lead sponsor

Medy-Tox is the lead sponsor of 49 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 75
  • Subjects had to have a confirmed clinical diagnosis of essential blepharospasm requiring treatment by injection

Exclusion criteria

Exclusion Criteria:

  • Subjects who underwent surgical operation
  • Subjects with Neuroleptic induced blepharospasm
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Neuronox

    Botulinum Toxin Type A for injection

    Drug: Neuronox

  • Active comparator
    Botox

    Botulinum Toxin Type A for injection

    Drug: Botox

Interventions

  • Clostridium Botulinum Toxin A 100 U

    Also known as: Botulinum Toxin Type A for injection

  • DrugBotox

    Clostridium Botulinum Toxin A 100 U

    Also known as: Botulinum Toxin Type A for injection

06

What researchers measure

Primary outcomes

  1. JRS (Jankovic Rating Scale) sum-score

    Change from baseline at 4 week for the JRS (Jankovic Rating Scale) sum-score

    Time frame: From baseline at 4 week

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Mar 2017, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2017
First posted
Jul 13, 2017
StartActual
May 25, 2016
Primary completionActual
Mar 17, 2017
CompletionActual
Jul 4, 2017
Last update
Jul 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03216473
Lead sponsor
Medy-Tox
Responsible party
Sponsor
First posted
Jul 13, 2017
Start date
May 25, 2016
Primary completion
Mar 17, 2017
Completion
Jul 4, 2017
Last update
Jul 13, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion